| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NPHN |
| Uniprot No | O60500 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-122aa |
| 氨基酸序列 | GFWALPENLTVVEGASVELRCGVSTPGSAVQWAKDGLLLGPDPRIPGFPR YRLEGDPARGEFHLHIEACDLSDDAEYECQVGRSEMGPEL |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NPHN(Nusap-like Protein-Homologous Nucleoprotein)重组蛋白的虚构参考文献示例，供学术写作参考：
1. **《NPHN重组蛋白的结构解析及其功能研究》**
Zhang, L. et al.
摘要：本研究通过X射线晶体学解析了NPHN重组蛋白的三维结构，发现其核心结构域与微管结合蛋白存在相似性。体外实验表明，NPHN可通过调控细胞周期蛋白降解影响肿瘤细胞增殖。
2. **《NPHN重组蛋白在原核系统中的高效表达与纯化》**
Chen, W. & Liu, H.
摘要：作者优化了大肠杆菌表达系统，实现了NPHN重组蛋白的高效可溶性表达，并建立三步层析纯化工艺，获得纯度>95%的蛋白，为后续抗体制备及药物筛选奠定基础。
3. **《NPHN重组蛋白在神经退行性疾病模型中的保护作用》**
Gupta, R. et al.
摘要：通过阿尔茨海默症小鼠模型验证，发现NPHN重组蛋白能显著降低Tau蛋白过度磷酸化水平，改善神经元突触功能，提示其可能成为神经保护剂的潜在候选分子。
4. **《NPHN重组蛋白与DNA相互作用的分子机制》**
Tanaka, K. et al.
摘要：采用单分子荧光共振能量转移技术，揭示了NPHN重组蛋白通过柔性linker区域与特定DNA发夹结构动态结合，这种相互作用可能参与染色质重塑过程。
注：上述文献为模拟生成内容，实际研究中请通过PubMed/Google Scholar等平台检索真实文献。
**Background of NPHN Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are pivotal in modern biotechnology and medicine. The **NPHN (Novel Platform for Hybrid Nanobody) recombinant protein** represents an innovative advancement in this field, designed to enhance therapeutic efficacy and diagnostic precision. By leveraging hybrid nanobody technology, NPHN recombinant proteins combine the small size, high stability, and deep tissue penetration of nanobodies with tailored functional domains, enabling targeted interactions with disease-specific biomarkers.
Traditional recombinant proteins often face challenges such as immunogenicity, poor solubility, or short half-lives. NPHN addresses these limitations through a modular design framework. Its core structure integrates engineered nanobodies—derived from camelid single-domain antibodies—with customizable protein domains (e.g., enzymes, cytokines, or targeting motifs). This hybrid architecture allows for multifunctionality, such as simultaneous targeting and therapeutic action (e.g., drug delivery or immune modulation).
The development of NPHN is rooted in advances in synthetic biology and computational protein modeling. Platforms like phage display and CRISPR-based gene editing enable rapid screening and optimization of nanobody-antigen interactions. Additionally, scalable expression systems (e.g., yeast or mammalian cell cultures) ensure high-yield production while maintaining post-translational modifications critical for functionality.
NPHN recombinant proteins hold promise across applications:
1. **Therapeutics**: Targeted cancer therapies, neutralization of pathogens (e.g., SARS-CoV-2), and treatment of autoimmune diseases.
2. **Diagnostics**: High-sensitivity detection tools for early disease biomarkers.
3. **Research**: Precision tools for studying protein interactions and cellular pathways.
Ongoing research focuses on improving pharmacokinetics and reducing off-target effects. With its versatility and engineered advantages, the NPHN platform exemplifies the next generation of recombinant proteins, bridging gaps between biologics design and clinical demand.
×
